Modulation of MK-801-elicited mouse popping behavior by galantamine is complex and dose-dependent

Life Sciences

Volumn 73, Issue 18, 2003, Pages 2355-2361

  Deutsch, Stephen I ^a,b,c,d   Rosse, Richard B ^a,b   Billingslea, Eddie N ^a   Bellack, Alan S ^a,c   Mastropaolo, John ^a  

^a Mental Health Service Line   (United States)

^b GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^d DEPARTMENT OF VETERANS AFFAIRS   (United States)

Author keywords

Galantamine; MK 801 (dizocilpine); NMDA receptor; Popping; Schizophrenia

Indexed keywords

ACETYLCHOLINESTERASE; DIZOCILPINE; GALANTAMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NICOTINIC RECEPTOR; PHENCYCLIDINE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; ENZYME INHIBITION; HYDROPHOBICITY; JUMPING; MALE; MOUSE; NEUROTRANSMISSION; NONHUMAN; POPPING BEHAVIOR; SCHIZOPHRENIFORM DISORDER; SIGNAL TRANSDUCTION; STATISTICAL ANALYSIS;

ANIMALIA;

EID: 0043073164     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0024-3205(03)00642-8     Document Type: Article

References (18)

1. Albuquerque E.X., Alkondon M., Pereira E.F.R., Castro N.G., Schrattenholz A., Barbosa C.T.F., Bonfante-Cabarcas R., Aracava Y., Eisenberg H.M., Maelicke A. Properties of neuronal nicotine acetylcholine receptors: pharmacological characterization and modulation of synaptic function. J Pharmacol Exp Ther. 280:1997;1117-1136.
2. Alkondon M., Pereira E.F.R., Cortes W.S., Maelicke A., Albuquerque E.X. Choline is a selective agonist of α7 nicotinic acetylcholine receptors in the rat brain neurons. European Journal of Neuroscience. 9:1997;2734-2742.
3. Braestrup C., Nielsen M. Benzodiazepine receptor binding in vivo and efficacy. Olsen R.W., Venter J.C. Benzodiazepine/GABA Receptors and Chloride Channels: Structural and Functional Properties. 1986;167-184 Alan R. Liss, New York, NY.
4. Coyle J.T. The glutamatergic dysfunction hypothesis for schizophrenia. Harvard Rev Psychiatry. 3:1996;241-253.
5. Deutsch S.I., Mastropaolo J., Schwartz B.L., Rosse R.B., Morihisa J.M. A "glutamatergic hypothesis" of schizophrenia: rationale for pharmacotherapy with glycine. Clin Neuropharmacol. 12(1):1989;1-13.
6. Deutsch S.I., Rosse R.B., Schwartz B.L., Mastropaolo J. A revised excitotoxic hypothesis of schizophrenia: therapeutic implications. Clin Neuropharmacol. 24:2001;43-49.
7. Farber N.B., Newcomer J.W., Olney J.W. The glutamate synapse in neuropsychiatric disorders. Prog Brain Res. 116:1998;421-437.
8. Freedman R., Hall M., Adler L.E., Leonard S. Evidence in postmortem brain tissue for decreased numbers of hippocampal nicotinic receptors in schizophrenia. Biol Psychiatry. 38(1):1995;22-33.
9. Guan Z.Z., Zhang X., Blennow K., Nordberg A. Decreased protein level of nicotinic receptor α7 subunit in the frontal cortex from schizophrenic brain. Neuroreport. 10:1999;1779-1782.
10. Haefely W., Polc P. Physiology of GABA enhancement by benzodiazepines and barbiturates. Olsen R.W., Venter J.C. Benzodiazepine/GABA Receptors and Chloride Channels: Structural and Functional Properties. 1986;97-133 Alan R. Liss, New York, NY.
11. Jentsch J.D., Roth R.H. The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology. 20:1999;201-225.
12. Maelicke A., Samochocki M., Jostock R., Fehrenbacher A., Ludwig J., Albuquerque E.X., Zerlin M. Allosteric sensitization of nicotinic receptors by galantamine, a new treatment strategy for Alzheimer's disease. Biol Psychiatry. 49(3):2001;279-288. (Feb 1).
13. Meltzer H.Y., Matsubara S., Lee J.C. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin pKi values. J Pharmacol Exp Ther. 251:1989;238-246.
14. Rosse R.B., Mastropaolo J., Koetzner L., Morn C.B., Sussman D.M., Deutsch S.I. Computer measurement of MK-801-elicited hyperactivity and popping in mice. Clin Neuropharmacol. 18:1995;448-457.
15. Samochocki M., Zerlin M., Jostock R., Groot Kormelink P.J., Luyten W.H., Albuquerque E.X., Maelicke A. Galantamine is an allosterically potentiating ligand of the human alpha4/beta2 nAChR. Acta Neurol Scand. (Suppl.). 176:2000;68-73.
16. Tamminga C.A. Schizophrenia and glutamatergic transmission. Crit Rev Neurobiol. 12:1998;21-36.
17. Tizabi Y., Mastropaolo J., Park C.H., Riggs R.L., Powell D., Rosse R.B., Deutsch S.I. Both nicotine and mecamylamine block dizocilpine-induced explosive jumping behavior in mice: psychiatric implications. Psychopharmacology. 140(2):1998;202-205.
18. Wamsley J.K., Gehlert D.R., Olsen R.W. The benzodiazepine/barbiturate-sensitive convulsant/GABA receptor/ chloride ionophore complex: autoradiographic localization of individual components. Olsen R.W., Venter J.C. Benzodiazepine/GABA Receptors and Chloride Channels: Structural and Functional Properties. 1986;299-313 Alan R. Liss, New York, NY.